ICU Medical, Inc. (NASDAQ:ICUI) Receives $127.00 Consensus Target Price from Analysts

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have been assigned a consensus rating of “Moderate Buy” from the four analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $127.00.

ICUI has been the subject of a number of research reports. Needham & Company LLC began coverage on ICU Medical in a report on Friday. They set a “hold” rating for the company. Raymond James upgraded ICU Medical from a “market perform” rating to an “outperform” rating and set a $135.00 price objective for the company in a report on Monday, June 17th. Finally, KeyCorp boosted their target price on ICU Medical from $134.00 to $136.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th.

Insider Buying and Selling

In related news, COO Christian B. Voigtlander sold 12,539 shares of the business’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $103.95, for a total transaction of $1,303,429.05. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, COO Christian B. Voigtlander sold 12,539 shares of ICU Medical stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $103.95, for a total transaction of $1,303,429.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ben Sousa sold 2,000 shares of the stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $105.55, for a total transaction of $211,100.00. Following the completion of the transaction, the insider now directly owns 1,319 shares in the company, valued at $139,220.45. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 14,839 shares of company stock worth $1,546,014. Company insiders own 6.70% of the company’s stock.

Institutional Trading of ICU Medical

Hedge funds and other institutional investors have recently bought and sold shares of the business. Motco acquired a new position in ICU Medical in the 1st quarter valued at $29,000. GAMMA Investing LLC raised its stake in ICU Medical by 75.1% in the first quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock valued at $33,000 after purchasing an additional 133 shares in the last quarter. EntryPoint Capital LLC lifted its position in ICU Medical by 731.5% during the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock worth $48,000 after purchasing an additional 395 shares during the period. CWM LLC grew its stake in ICU Medical by 341.2% during the fourth quarter. CWM LLC now owns 578 shares of the medical instruments supplier’s stock worth $58,000 after buying an additional 447 shares in the last quarter. Finally, Quadrant Capital Group LLC grew its stake in ICU Medical by 681.6% during the fourth quarter. Quadrant Capital Group LLC now owns 594 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 518 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Stock Down 3.7 %

Shares of NASDAQ ICUI opened at $116.10 on Friday. ICU Medical has a 1 year low of $78.28 and a 1 year high of $182.62. The firm’s 50-day moving average is $104.85 and its 200-day moving average is $101.16. The company has a current ratio of 2.61, a quick ratio of 1.09 and a debt-to-equity ratio of 0.76. The firm has a market capitalization of $2.83 billion, a PE ratio of -47.39 and a beta of 0.73.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Tuesday, May 7th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.54 by $0.06. The firm had revenue of $566.66 million during the quarter, compared to analysts’ expectations of $553.15 million. ICU Medical had a negative net margin of 2.63% and a positive return on equity of 5.38%. Equities analysts expect that ICU Medical will post 3.5 EPS for the current year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.